Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

Let’s Meet to Discuss Bioanalytical, Biomarker, and Transitioning to Early Safety Studies.

Celerion, a full-service, early clinical CRO, is the leader in accelerating development for Phase I-IIb. Our unique combination of medical expertise, clinical operations experience and scientific excellence, enables you to make timely decisions with expert advice and high-quality data.

For over fifty years, Celerion has leveraged the latest operational concepts and technologies to execute safety/tolerability, pharmacokinetic, and pharmacodynamic studies in highly controlled clinical environments. These include first-in-human dose escalation, drug-drug interaction, cardiac safety, bioequivalence and bioavailability, metabolism, and excretion studies, as well as pharmacokinetic evaluations in patients with impaired renal or hepatic function. In addition, Celerion offers data management, biostatistics, clinical monitoring, and bioanalytical services.

Integrated drug development requires a multidisciplinary approach to understand how manufacturing, pharmacology and toxicology contribute to regulatory strategy and to elements of clinical study design and conduct. The knowledge and leadership of our highly trained scientists significantly streamline the early clinical development process, enabling you to minimize costs and make more informed decisions. Our integrated services span small and large molecule drugs, vaccines, and other therapies, from preclinical testing through clinical proof-of-concept all the way to full clinical development.

Let’s meet to discuss your drug development program!